Psychiatric and Neurodevelopmental Genetics Unit, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Center for Precision Psychiatry, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Mol Psychiatry. 2022 Mar;27(3):1405-1415. doi: 10.1038/s41380-022-01490-1. Epub 2022 Mar 8.
A missense mutation (A391T) in SLC39A8 is strongly associated with schizophrenia in genomic studies, though the molecular connection to the brain is unknown. Human carriers of A391T have reduced serum manganese, altered plasma glycosylation, and brain MRI changes consistent with altered metal transport. Here, using a knock-in mouse model homozygous for A391T, we show that the schizophrenia-associated variant changes protein glycosylation in the brain. Glycosylation of Asn residues in glycoproteins (N-glycosylation) was most significantly impaired, with effects differing between regions. RNAseq analysis showed negligible regional variation, consistent with changes in the activity of glycosylation enzymes rather than gene expression. Finally, nearly one-third of detected glycoproteins were differentially N-glycosylated in the cortex, including members of several pathways previously implicated in schizophrenia, such as cell adhesion molecules and neurotransmitter receptors that are expressed across all cell types. These findings provide a mechanistic link between a risk allele and potentially reversible biochemical changes in the brain, furthering our molecular understanding of the pathophysiology of schizophrenia and a novel opportunity for therapeutic development.
在基因组研究中,SLC39A8 中的错义突变(A391T)与精神分裂症强烈相关,尽管其与大脑的分子联系尚不清楚。携带 A391T 的人类血清锰减少,血浆糖基化改变,脑 MRI 改变与金属转运改变一致。在这里,我们使用纯合 A391T 的敲入小鼠模型表明,与精神分裂症相关的变体改变了大脑中的蛋白质糖基化。糖蛋白中天冬酰胺残基的糖基化(N-糖基化)受到最显著的损害,并且在不同区域之间存在差异。RNAseq 分析表明,区域变化可忽略不计,这与糖基化酶的活性变化而不是基因表达一致。最后,在皮质中,近三分之一的检测到的糖蛋白的 N-糖基化存在差异,包括几种先前与精神分裂症相关的途径中的成员,例如细胞粘附分子和神经递质受体,这些受体在所有细胞类型中均有表达。这些发现为风险等位基因与大脑中潜在可逆转的生化变化之间提供了一种机制联系,进一步加深了我们对精神分裂症病理生理学的分子理解,并为治疗开发提供了新的机会。